EDIT Stock Forecast: Editas Medicine, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Editas Medicine, Inc. is $5.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 67 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Editas Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (80): Sales and profits are climbing, and climbing faster than before.
Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EDIT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EDIT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | Wells Fargo | Upgrade | Overweight | $4.00 → $6.00 |
| 23 Sept 2026 | Guggenheim | Upgrade | Buy | $5.00 |
| 18 Aug 2026 | Ladenburg Thalmann | Initiates | Buy | — |
| 5 May 2026 | Chardan Capital | Maintains | Buy | $3.50 → $4.00 |
| 10 Mar 2026 | Jones Trading | Upgrade | Buy | — |
| 9 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 5 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2025 | Baird | Maintains | Outperform | — |
| 13 May 2025 | Baird | Maintains | Outperform | — |
| 28 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Dec 2024 | Evercore ISI Group | Maintains | Outperform | — |
| 16 Dec 2024 | JP Morgan | Downgrade | Underweight | — |
| 13 Dec 2024 | Baird | Maintains | Outperform | — |
| 13 Dec 2024 | Barclays | Maintains | Equal-Weight | — |
| 13 Dec 2024 | Chardan Capital | Downgrade | Neutral | — |
| 13 Dec 2024 | RBC Capital | Maintains | Sector Perform | — |
| 13 Dec 2024 | Stifel | Downgrade | Hold | — |
| 11 Dec 2024 | Wells Fargo | Downgrade | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EDIT.
This page is one stock. Monday covers all of them.
EDIT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EDIT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Editas Medicine, Inc. returned −33.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EDIT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.1×
- Price / book
- 3.0×
- EV / EBITDA
- —
Cheaper than 21% of US stocks
Cheaper than 31% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −147.4%
- Return on assets
- −24.7%
- Dividend yield
- —
Higher than 10% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Editas Medicine, Inc. has a market value of $253.1M and an enterprise value of $76.9M.
Revenue in the twelve months to 30 June 2026: $47.0M. The latest quarter grew 232.3% year on year.
Net income over the same four quarters: −$73.9M, a −157.3% net margin.
Diluted earnings per share, trailing twelve months: −$0.75.
Free cash flow in the twelve months to 30 June 2026: −$120.5M.
Editas Medicine, Inc. employs 87 people — $540K of revenue per employee.
Data provided by Twelve Data
EDIT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EDIT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Editas Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EDIT
What is the EDIT stock price forecast for 2026-2027?
The median 12-month analyst price target for Editas Medicine, Inc. is $5.5, with estimates ranging from $1 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EDIT stock a buy right now?
Of the 13 analysts covering Editas Medicine, Inc., 9 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Editas Medicine, Inc. 67 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EDIT?
As at 21 Nov 2026, Editas Medicine, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (80 of 100).
Will EDIT stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts is $5.5, and Ticker Nerd's factor model ranks Editas Medicine, Inc. 67 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EDIT stock forecast for 2030?
No analyst covering Editas Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDIT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $15 over the next 12 months.
How has EDIT stock performed over the past year?
Editas Medicine, Inc. returned -33.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Editas Medicine, Inc. do?
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions.
About Editas Medicine, Inc.
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions. Its current development efforts include in vivo and ex vivo programs aimed at areas such as hematology, cardiovascular disease, and other severe disorders with limited treatment options. Editas Medicine also maintains collaborations and intellectual property positions that support its research platform and pipeline. Headquartered in Cambridge, Massachusetts, the company plays a specialized role in the gene editing market by advancing experimental medicines intended to address diseases at the DNA level.
CEO Dr. Gilmore O'Neill M.D. · 87 employees · United States · https://www.editasmedicine.com